A citation-based method for searching scientific literature

Meng Xu, Peter P Liu, Hongliang Li. Physiol Rev 2019
Times Cited: 42







List of co-cited articles
259 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases.
Jingjing Cai, Meng Xu, Xiaojing Zhang, Hongliang Li. Annu Rev Pathol 2019
44
35

Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease.
Jingjing Cai, Xiao-Jing Zhang, Hongliang Li. Trends Endocrinol Metab 2018
44
26

The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis.
Peng Zhang, Pi-Xiao Wang, Ling-Ping Zhao, Xin Zhang, Yan-Xiao Ji, Xiao-Jing Zhang, Chun Fang, Yue-Xin Lu, Xia Yang, Mao-Mao Gao,[...]. Nat Med 2018
118
23

The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.
Yan-Xiao Ji, Zan Huang, Xia Yang, Xiaozhan Wang, Ling-Ping Zhao, Pi-Xiao Wang, Xiao-Jing Zhang, Michele Alves-Bezerra, Lin Cai, Peng Zhang,[...]. Nat Med 2018
79
21

Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4.
Guang-Nian Zhao, Peng Zhang, Jun Gong, Xiao-Jing Zhang, Pi-Xiao Wang, Miao Yin, Zhou Jiang, Li-Jun Shen, Yan-Xiao Ji, Jingjing Tong,[...]. Nat Med 2017
93
21

The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.
Feng-Juan Yan, Xiao-Jing Zhang, Wen-Xin Wang, Yan-Xiao Ji, Pi-Xiao Wang, Yang Yang, Jun Gong, Li-Jun Shen, Xue-Yong Zhu, Zan Huang,[...]. Hepatology 2017
52
21

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases.
Yao Yu, Jingjing Cai, Zhigang She, Hongliang Li. Adv Sci (Weinh) 2018
77
21

Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease.
Ze Chen, Yao Yu, Jingjing Cai, Hongliang Li. Trends Endocrinol Metab 2019
57
21

Progress and challenges in the prevention and control of nonalcoholic fatty liver disease.
Jingjing Cai, Xiao-Jing Zhang, Hongliang Li. Med Res Rev 2019
69
19

Time to step-up the fight against NAFLD.
Xiao-Jing Zhang, Zhi-Gang She, Hongliang Li. Hepatology 2018
24
33

Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.
Pi-Xiao Wang, Yan-Xiao Ji, Xiao-Jing Zhang, Ling-Ping Zhao, Zhen-Zhen Yan, Peng Zhang, Li-Jun Shen, Xia Yang, Jing Fang, Song Tian,[...]. Nat Med 2017
142
16

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
16

Reprogramming Innate Immune Signaling in Cardiometabolic Disease.
Yaxing Zhang, Xiao-Jing Zhang, Pi-Xiao Wang, Peng Zhang, Hongliang Li. Hypertension 2017
19
36

The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis.
Jingjing Cai, Xiao-Jing Zhang, Hongliang Li. Hepatology 2019
91
16

Innate immune regulatory networks in hepatic lipid metabolism.
Lan Bai, Hongliang Li. J Mol Med (Berl) 2019
34
20

Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling.
Pi-Xiao Wang, Xiao-Jing Zhang, Pengcheng Luo, Xi Jiang, Peng Zhang, Junhong Guo, Guang-Nian Zhao, Xueyong Zhu, Yan Zhang, Sijun Yang,[...]. Nat Commun 2016
94
14

Mechanisms of NAFLD development and therapeutic strategies.
Scott L Friedman, Brent A Neuschwander-Tetri, Mary Rinella, Arun J Sanyal. Nat Med 2018
14

DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity.
Lanfeng Xie, Pi-Xiao Wang, Peng Zhang, Xiao-Jing Zhang, Guang-Nian Zhao, Aibing Wang, Junhong Guo, Xueyong Zhu, Qin Zhang, Hongliang Li. J Hepatol 2016
47
11

Hepatic Oncostatin M Receptor β Regulates Obesity-Induced Steatosis and Insulin Resistance.
Pengcheng Luo, Pi-Xiao Wang, Zuo-Zhi Li, Xiao-Jing Zhang, Xi Jiang, Jun Gong, Juan-Juan Qin, Junhong Guo, Xueyong Zhu, Sijun Yang,[...]. Am J Pathol 2016
24
20

Reprogramming Interferon Regulatory Factor Signaling in Cardiometabolic Diseases.
Yaxing Zhang, Hongliang Li. Physiology (Bethesda) 2017
22
22

The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling.
Yan-Xiao Ji, Peng Zhang, Xiao-Jing Zhang, Yi-Chao Zhao, Ke-Qiong Deng, Xi Jiang, Pi-Xiao Wang, Zan Huang, Hongliang Li. Nat Commun 2016
117
11

Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor γ in Mice.
Jingjing Tong, Cui-Juan Han, Jia-Zhen Zhang, Wen-Zhi He, Guo-Jun Zhao, Xu Cheng, Lei Zhang, Ke-Qiong Deng, Ye Liu, Hui-Fen Fan,[...]. Hepatology 2019
26
19


The innate immune signaling in cancer and cardiometabolic diseases: Friends or foes?
Weijun Wang, Yaxing Zhang, Ling Yang, Hongliang Li. Cancer Lett 2017
15
33

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Fei Zhou, Ting Yu, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Jie Xiang, Yeming Wang, Bin Song, Xiaoying Gu,[...]. Lancet 2020
11

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
9

Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis.
Mei Xiang, Pi-Xiao Wang, Ai-Bing Wang, Xiao-Jing Zhang, Yaxing Zhang, Peng Zhang, Fang-Hua Mei, Man-Hua Chen, Hongliang Li. J Hepatol 2016
96
9

Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
Li-Hua Zhu, Aibing Wang, Pengcheng Luo, Xinan Wang, Ding-Sheng Jiang, Wei Deng, Xiaofei Zhang, Tao Wang, Yi Liu, Lu Gao,[...]. J Hepatol 2014
41
9

Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver.
Siyuan Wang, Zhen-Zhen Yan, Xia Yang, Shimin An, Kuo Zhang, Yu Qi, Jilin Zheng, Yan-Xiao Ji, Pi-Xiao Wang, Chun Fang,[...]. Hepatology 2018
34
11

Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.
Ling Gao, Pi-Xiao Wang, Yaxing Zhang, Chang-Jiang Yu, Yanxiao Ji, Xiaozhan Wang, Peng Zhang, Xi Jiang, Hong Jin, Zan Huang,[...]. J Hepatol 2016
36
11


Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
9

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
9

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
961
9

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Vlad Ratziu, Stephen A Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Steve Caldwell,[...]. Gastroenterology 2016
646
9

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Zobair Younossi, Frank Tacke, Marco Arrese, Barjesh Chander Sharma, Ibrahim Mostafa, Elisabetta Bugianesi, Vincent Wai-Sun Wong, Yusuf Yilmaz, Jacob George, Jiangao Fan,[...]. Hepatology 2019
724
9

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Brent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, Joel E Lavine, Mark L Van Natta, Manal F Abdelmalek, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Bilal Hameed,[...]. Lancet 2015
9

Interferon regulatory factor signalings in cardiometabolic diseases.
Xiao-Jing Zhang, Peng Zhang, Hongliang Li. Hypertension 2015
40
10

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Rohit Loomba, Zeid Kayali, Mazen Noureddin, Peter Ruane, Eric J Lawitz, Michael Bennett, Lulu Wang, Eliza Harting, Jacqueline M Tarrant, Bryan J McColgan,[...]. Gastroenterology 2018
175
9

Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Juan Pablo Arab, Marco Arrese, Michael Trauner. Annu Rev Pathol 2018
242
9

CARD3 deficiency exacerbates diet-induced obesity, hepatosteatosis, and insulin resistance in male mice.
Xin-An Wang, Shan Deng, Dingsheng Jiang, Ran Zhang, Shumin Zhang, Jinfeng Zhong, Li Yang, Tao Wang, Shufen Hong, Sen Guo,[...]. Endocrinology 2013
20
20

Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.
Ruth C R Meex, Matthew J Watt. Nat Rev Endocrinol 2017
295
9

Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6-Linked Polyubiquitination of Apoptosis Signal-Regulating Kinase 1.
Yutao Wang, Huan Wen, Jiajun Fu, Lin Cai, Peng-Long Li, Chang-Ling Zhao, Zhu-Feng Dong, Jun-Peng Ma, Xi Wang, Han Tian,[...]. Hepatology 2020
42
9

Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension.
Yan-Ci Zhao, Guo-Jun Zhao, Ze Chen, Zhi-Gang She, Jingjing Cai, Hongliang Li. Hypertension 2020
58
9

Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study.
Angus Forbes, Trevor Murrells, Henrietta Mulnier, Alan J Sinclair. Lancet Diabetes Endocrinol 2018
88
9

Influence of diabetes mellitus on immunity to human tuberculosis.
Pavan Kumar Nathella, Subash Babu. Immunology 2017
85
9

Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease.
Ze Chen, Ruifeng Tian, Zhigang She, Jingjing Cai, Hongliang Li. Free Radic Biol Med 2020
261
9

Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases.
Jingjing Cai, Xiao-Jing Zhang, Yan-Xiao Ji, Peng Zhang, Zhi-Gang She, Hongliang Li. Circ Res 2020
76
9

Role of Aramchol in steatohepatitis and fibrosis in mice.
Marta Iruarrizaga-Lejarreta, Marta Varela-Rey, David Fernández-Ramos, Ibon Martínez-Arranz, Teresa C Delgado, Jorge Simon, Virginia Gutiérrez-de Juan, Laura delaCruz-Villar, Mikel Azkargorta, José L Lavin,[...]. Hepatol Commun 2017
63
7

Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.
Geraldine Harriman, Jeremy Greenwood, Sathesh Bhat, Xinyi Huang, Ruiying Wang, Debamita Paul, Liang Tong, Asish K Saha, William F Westlin, Rosana Kapeller,[...]. Proc Natl Acad Sci U S A 2016
167
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.